OIFE Investigator Meeting 2026 – final program

13 November 2026 14:00-19:00 CET

14:00 – 14:05	**Welcome and introduction**
14:05 – 14:45	**Session 1 Diagnostic complexity and new developments in bone** *Moderators: Dimitra Micha and Michael Stewart*
14:05 – 14:20	**Genetic vs. clinical diagnosis – where does OI start and stop?** Frank Rauch, Canada
14:20 – 14:35	**Cellular and genetic determinants of OI and other skeletal diseases** Ryan Chai, Australia
14:35 – 14:45	**Q&A & discussion**
14:45 – 15:25	**Session 2 Submitted abstracts – clinical research** *Moderators: Lena Lande Wekre and Josephine Tauer*
14:45	**Dental Manifestations and Genotype-Phenotype Associations in Children with Osteogenesis Imperfecta,** Nur Syaheera Binti Tajuddin, UK/Malaysia
14:55	**Treatment with a higher dose of sclerostin neutralizing antibody improved mechanoregulation in adults with severe osteogenesis imperfecta,** Pedram Akhlaghi, Canada
15:05	**Dental Proteomic Analysis in a Pediatric Population with Osteogenesis Imperfecta,** Marta Macarena Paz Cortes, Spain
15:15	**Longitudinal Evaluation of Pain and Functioning Following Intravenous Pamidronate in Osteogenesis Imperfecta: The Impact of Age and Disease Severity,** Andrew Stolfe, USA
15:25-15:35	*Comfort break (10 minutes)*
15:35 – 16:30	**Session 3 Variability & Complexity in OI** *Moderators: Dimitra Micha and Taco van Welzenis*
15:35 – 15:50	**Variability and reduced penetrance in COL1A1/2: lessons from population data and newborn genome screening** Meena Balasubramanian, UK

15.50 – 16.00	**The Role of Bone Marrow Microenvironment in Osteogenesis Imperfecta: Evidence from Single-Cell RNA Sequencing** Kelly Warmink, The Netherlands
16.00 – 16.10	**The Metabolic Complexity of Osteogenesis Imperfecta** Josephine Tauer, Austria
16.10 – 16.20	**Cross-link levels of collagen in bone of OI patients with various disease severity** Wouter Nijhuis, The Netherlands.
16:20 – 16:30	Q&A and discussion
16:30 – 17:10 16:30 16:40 16.50 17:00	**Session 4 Submitted abstracts – basic research** *Moderators Lidiia Zhytnik and Inger-Margrethe S. Paulsen* **KOL17091, a First-in-Class Dual GIP/GLP-2 Analogue, Strongly Protects Against Skeletal Fragility in Type III Osteogenesis Imperfecta,** Guillaume Mabilleau, France **Reclassification of variants of uncertain significance in type 1 collagen genes towards generation of zebrafish model for functional validation,** Nurhaziqah B Supari, UK **Skeletal Muscle Weakness in the Cartilage-associated protein knockout (CrtapKO) Mouse Model of Osteogenesis Imperfecta,** Shafina Jahan, USA **Altered MSC- HSC Crosstalk in Osteogenesis Imperfecta: Implications for Bone Marrow Niche Function** Agnes Selina, India
17:10 – 17.20	*Comfort break (10 minutes)*
17:20 – 18:55	**Session 5: Bone quality vs. bone density – how do we measure what is relevant for both patients, clinicians and regulators?** *Moderators: Ingunn Westerheim and Lars Folkestad*
17:20 – 17:35	**Lessons learned from Cosmic and Orbit** Raja Padidela, UK
17:35 – 17.50	**The Pathway to Clinical Micro-Computed Tomography: HR-pQCT to Photon-Counting CT** Andrew Burghardt, USA

17.50 – 18:00	**From Pain to Patient Preferences Patient Engagement in Early HTA for Repurposing Losartan in Osteogenesis Imperfecta** Reka Pozsar, Hungary
18:00 – 18:10	**Pain & fatigue in OI – why is it so complicated to measure?** Jacqui Clinch, UK
18:10 – 18:20	**Measuring mobility in OI and rare bone conditions** Edward Hsiao, USA
18:20 – 18:30	**Composite endpoints in clinical trials on rare diseases: when combining outcomes helps - and when it misleads** Johan Verbeeck, Belgium
18:30 – 18:40	**Rethinking OI treatment after TOPAZ: how to improve bone quality vs. bone density** Stuart Ralston, UK
18:40 – 18:55	**Q&A and discussion - What is the best way to measure meaningful impact of interventions in children and adults with OI?**
18:55	**Summing up and practical info** Ingunn Westerheim
19:00	*Close*